

Exome sequencing identifies somatic gain-of-function *PTEN* mutations in gliomas

Nature Genetics

46, 726-730

DOI: 10.1038/ng.2995

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Management of diffuse intrinsic pontine glioma in children: current and future strategies for improving prognosis. <i>CNS Oncology</i> , 2014, 3, 421-431. | 3.0 | 21 |
| 2 | Pax3 expression enhances PDGF-B-induced brainstem gliomagenesis and characterizes a subset of brainstem glioma. <i>Acta Neuropathologica Communications</i> , 2014, 2, 134. | 5.2 | 27 |
| 3 | Smaller protein, larger therapeutic potential: PPM1D as a new therapeutic target in brainstem glioma. <i>Pharmacogenomics</i> , 2014, 15, 1639-1641. | 1.3 | 4 |
| 4 | Inhibition of C-terminal truncated PPM1D enhances the effect of doxorubicin on cell viability in human colorectal carcinoma cell line. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 5593-5596. | 2.2 | 10 |
| 5 | Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence. <i>New England Journal of Medicine</i> , 2014, 371, 2477-2487. | 27.0 | 2,669 |
| 6 | A sensitive and specific histopathologic prognostic marker for H3F3A K27M mutant pediatric glioblastomas. <i>Acta Neuropathologica</i> , 2014, 128, 743-753. | 7.7 | 114 |
| 7 | Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of CNS oncology. <i>CNS Oncology</i> , 2014, 3, 317-319. | 3.0 | 0 |
| 8 | PM-12 * Pax3 EXPRESSION ENHANCES PDGF-B-INDUCED BRAINSTEM GLIOMAGENESIS AND CHARACTERIZES A SUBSET OF BRAINSTEM GLIOMA. <i>Neuro-Oncology</i> , 2014, 16, v171-v171. | 1.2 | 0 |
| 9 | The catalytic role of the M2 metal ion in PP2C \hat{I} . <i>Scientific Reports</i> , 2015, 5, 8560. | 3.3 | 17 |
| 10 | Comparative transcriptomics reveals similarities and differences between astrocytoma grades. <i>BMC Cancer</i> , 2015, 15, 952. | 2.6 | 38 |
| 11 | Identification of <i>para</i> -Substituted Benzoic Acid Derivatives as Potent Inhibitors of the Protein Phosphatase Slingshot. <i>ChemMedChem</i> , 2015, 10, 1980-1987. | 3.2 | 9 |
| 12 | Oncogenes and tumor suppressor genes: comparative genomics and network perspectives. <i>BMC Genomics</i> , 2015, 16, S8. | 2.8 | 41 |
| 13 | The historical change of brainstem glioma diagnosis and treatment: from imaging to molecular pathology and then molecular imaging. <i>Chinese Neurosurgical Journal</i> , 2015, 1, . | 0.9 | 4 |
| 14 | Pathology, Molecular Genetics, and Epigenetics of Diffuse Intrinsic Pontine Glioma. <i>Frontiers in Oncology</i> , 2015, 5, 147. | 2.8 | 91 |
| 15 | WIP1 Phosphatase as a Potential Therapeutic Target in Neuroblastoma. <i>PLoS ONE</i> , 2015, 10, e0115635. | 2.5 | 57 |
| 16 | Next-Generation Sequencing-Based Panel Testing for Myeloid Neoplasms. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 104-111. | 2.3 | 35 |
| 17 | Next-generation (epi)genetic drivers of childhood brain tumours and the outlook for targeted therapies. <i>Lancet Oncology</i> , The, 2015, 16, e293-e302. | 10.7 | 72 |
| 18 | Cancer genomics: why rare is valuable. <i>Journal of Molecular Medicine</i> , 2015, 93, 369-381. | 3.9 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Inhibition of wild-type p53-induced phosphatase 1 promotes liver regeneration in mice by direct activation of mammalian target of rapamycin. <i>Hepatology</i> , 2015, 61, 2030-2041. | 7.3 | 28 |
| 20 | Genetic investigations on intracranial aneurysm: Update and perspectives. <i>Journal of Neuroradiology</i> , 2015, 42, 67-71. | 1.1 | 25 |
| 21 | Approaches Toward Improving the Prognosis of Pediatric Patients With Glioma: Pursuing Mutant Drug Targets With Emerging Small Molecules. <i>Seminars in Pediatric Neurology</i> , 2015, 22, 28-34. | 2.0 | 11 |
| 22 | Progress in the application of molecular biomarkers in gliomas. <i>Biochemical and Biophysical Research Communications</i> , 2015, 465, 1-4. | 2.1 | 50 |
| 23 | The H3.3 K27M mutation results in a poorer prognosis in brainstem gliomas than thalamic gliomas in adults. <i>Human Pathology</i> , 2015, 46, 1626-1632. | 2.0 | 88 |
| 24 | Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients. <i>British Journal of Cancer</i> , 2015, 112, 1114-1120. | 6.4 | 46 |
| 25 | Clinicopathology of diffuse intrinsic pontine glioma and its redefined genomic and epigenomic landscape. <i>Cancer Genetics</i> , 2015, 208, 367-373. | 0.4 | 35 |
| 26 | The genomic landscape of papillary thyroid carcinoma. <i>Nature Reviews Endocrinology</i> , 2015, 11, 133-134. | 9.6 | 12 |
| 27 | Wip1 phosphatase in breast cancer. <i>Oncogene</i> , 2015, 34, 4429-4438. | 5.9 | 40 |
| 28 | Diffuse Intrinsic Pontine Glioma: A Therapeutic Challenge. , 0, , . | | 0 |
| 29 | HG-76SPATIAL AND TEMPORAL HOMOGENEITY OF DRIVER MUTATIONS IN DIFFUSE INTRINSIC PONTINE GLIOMA. <i>Neuro-Oncology</i> , 2016, 18, iii66.1-iii66. | 1.2 | 0 |
| 30 | High-Grade Glioma of the Ventrolateral Medulla in an Adult: Case Presentation and Discussion of Surgical Considerations. <i>Case Reports in Neurological Medicine</i> , 2016, 2016, 1-9. | 0.4 | 1 |
| 31 | Brainstem Glioma in Adults. <i>Frontiers in Oncology</i> , 2016, 6, 180. | 2.8 | 42 |
| 32 | Genetic mutations in high grade gliomas of the adult spinal cord. <i>Brain Tumor Pathology</i> , 2016, 33, 267-269. | 1.7 | 26 |
| 33 | Diffuse Midline Gliomas with Histone <sc>H3</sc>K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations. <i>Brain Pathology</i> , 2016, 26, 569-580. | 4.1 | 334 |
| 34 | Posterior Fossa Tumors. <i>Journal of Pediatric Neuroradiology</i> , 2016, 05, 089-110. | 0.1 | 2 |
| 35 | RNaseH2A is involved in human gliomagenesis through the regulation of cell proliferation and apoptosis. <i>Oncology Reports</i> , 2016, 36, 173-180. | 2.6 | 16 |
| 36 | Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. <i>Nature Communications</i> , 2016, 7, 11185. | 12.8 | 197 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 379-391. | 4.1 | 36 |
| 38 | The value of research collaborations and consortia in rare cancers. <i>Lancet Oncology</i> , The, 2016, 17, e62-e69. | 10.7 | 89 |
| 39 | SARI , a novel target gene of glucocorticoid receptor, plays an important role in dexamethasone-mediated killing of B lymphoma cells. <i>Cancer Letters</i> , 2016, 373, 57-66. | 7.2 | 19 |
| 40 | Expression and gene doses changes of the p53-regulator PPM1D in meningiomas: a role in meningioma progression?. <i>Brain Tumor Pathology</i> , 2016, 33, 191-199. | 1.7 | 5 |
| 41 | Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. <i>Neuro-Oncology</i> , 2017, 19, now294. | 1.2 | 54 |
| 42 | WIP1 phosphatase as pharmacological target in cancer therapy. <i>Journal of Molecular Medicine</i> , 2017, 95, 589-599. | 3.9 | 48 |
| 43 | Wild-type p53-induced phosphatase 1 is a prognostic marker and therapeutic target in bladder transitional cell carcinoma. <i>Oncology Letters</i> , 2017, 13, 875-880. | 1.8 | 6 |
| 44 | LZAP is a novel Wip1 binding partner and positive regulator of its phosphatase activity <i>in vitro</i> . <i>Cell Cycle</i> , 2017, 16, 213-223. | 2.6 | 14 |
| 45 | Role of wild-type p53-induced phosphatase 1 in cancer. <i>Oncology Letters</i> , 2017, 14, 3893-3898. | 1.8 | 20 |
| 46 | Pediatric Thalamic Gliomas: An Updated Review. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 1316-1323. | 2.5 | 22 |
| 47 | Distinct molecular profile of diffuse cerebellar gliomas. <i>Acta Neuropathologica</i> , 2017, 134, 941-956. | 7.7 | 40 |
| 48 | Molecular landscape of pediatric diffuse intrinsic pontine gliomas: about 22 cases. <i>Journal of Neuro-Oncology</i> , 2017, 134, 465-467. | 2.9 | 3 |
| 49 | Molecular pathology of paediatric central nervous system tumours. <i>Journal of Pathology</i> , 2017, 241, 159-172. | 4.5 | 51 |
| 50 | Potential New Therapies for Pediatric Diffuse Intrinsic Pontine Glioma. <i>Frontiers in Pharmacology</i> , 2017, 8, 495. | 3.5 | 48 |
| 51 | Convection enhanced delivery of panobinostat (LBH589)-loaded pluronic nano-micelles prolongs survival in the F98 rat glioma model. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 1385-1399. | 6.7 | 47 |
| 52 | Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas. <i>Acta Neuropathologica Communications</i> , 2017, 5, 78. | 5.2 | 48 |
| 53 | Genetic and immune features of resectable malignant brainstem gliomas. <i>Oncotarget</i> , 2017, 8, 82571-82582. | 1.8 | 12 |
| 54 | Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review). <i>International Journal of Oncology</i> , 2018, 52, 1041-1056. | 3.3 | 4 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 55 | The clinicopathological and prognostic significance of TP53 alteration in K27M mutated gliomas: an individual-participant data meta-analysis. <i>Neurological Sciences</i> , 2018, 39, 1191-1201. | 1.9 | 7 |
| 56 | Histone H3.3K27M Mobilizes Multiple Cancer/Testis (CT) Antigens in Pediatric Glioma. <i>Molecular Cancer Research</i> , 2018, 16, 623-633. | 3.4 | 10 |
| 57 | New Directions in the Treatment of Glioblastoma. <i>Seminars in Neurology</i> , 2018, 38, 050-061. | 1.4 | 33 |
| 58 | Shared ACVR1 mutations in FOP and DIPG: Opportunities and challenges in extending biological and clinical implications across rare diseases. <i>Bone</i> , 2018, 109, 91-100. | 2.9 | 25 |
| 59 | Diffuse Intrinsic Pontine Glioma. , 0, , . | | 3 |
| 60 | Genetic Landscape of Thyroid Cancer. , 2018, , 41-52. | | 0 |
| 61 | High-Grade Glioma, Including Diffuse Intrinsic Pontine Glioma. , 2018, , 193-221. | | 0 |
| 62 | Classification and Personalized Prognosis in Myeloproliferative Neoplasms. <i>New England Journal of Medicine</i> , 2018, 379, 1416-1430. | 27.0 | 442 |
| 63 | PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy. <i>Cell Stem Cell</i> , 2018, 23, 700-713.e6. | 11.1 | 272 |
| 64 | The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma. <i>Nature Communications</i> , 2018, 9, 2087. | 12.8 | 124 |
| 65 | Wip1 knockout inhibits neurogenesis by affecting the Wnt/ β -catenin signaling pathway in focal cerebral ischemia in mice. <i>Experimental Neurology</i> , 2018, 309, 44-53. | 4.1 | 31 |
| 66 | CDK4/6 and PDGFRA Signaling as Therapeutic Targets in Diffuse Intrinsic Pontine Glioma. <i>Frontiers in Oncology</i> , 2018, 8, 191. | 2.8 | 18 |
| 67 | <i>FGFR1</i> actionable mutations, molecular specificities, and outcome of adult midline gliomas. <i>Neurology</i> , 2018, 90, e2086-e2094. | 1.1 | 47 |
| 68 | Mutant allele quantification reveals a genetic basis for TP53 mutation-driven castration resistance in prostate cancer cells. <i>Scientific Reports</i> , 2018, 8, 12507. | 3.3 | 5 |
| 69 | A machine learning-based prediction model of H3K27M mutations in brainstem gliomas using conventional MRI and clinical features. <i>Radiotherapy and Oncology</i> , 2019, 130, 172-179. | 0.6 | 42 |
| 70 | Truncated PPM1D impairs stem cell response to genotoxic stress and promotes growth of APC-deficient tumors in the mouse colon. <i>Cell Death and Disease</i> , 2019, 10, 818. | 6.3 | 12 |
| 71 | PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma. <i>Nature Communications</i> , 2019, 10, 3790. | 12.8 | 54 |
| 72 | Malignant Intramedullary Spinal Cord Tumors. , 2019, , 337-364. | | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 73 | Signal transduction pathways and resistance to targeted therapies in glioma. <i>Seminars in Cancer Biology</i> , 2019, 58, 118-129. | 9.6 | 40 |
| 74 | Somatic mosaic truncating mutations of PPM1D in blood can result from expansion of a mutant clone under selective pressure of chemotherapy. <i>PLoS ONE</i> , 2019, 14, e0217521. | 2.5 | 7 |
| 75 | Spinal cord high-grade infiltrating gliomas in adults: clinico-pathological and molecular evaluation. <i>Modern Pathology</i> , 2019, 32, 1236-1243. | 5.5 | 44 |
| 76 | Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma. <i>Neuro-Oncology</i> , 2019, 21, 786-799. | 1.2 | 26 |
| 77 | Batch adjustment by reference alignment (BARA): Improved prediction performance in biological test sets with batch effects. <i>PLoS ONE</i> , 2019, 14, e0212669. | 2.5 | 3 |
| 78 | TP53 Pathway Alterations Drive Radioresistance in Diffuse Intrinsic Pontine Gliomas (DIPG). <i>Clinical Cancer Research</i> , 2019, 25, 6788-6800. | 7.0 | 66 |
| 79 | CRISPR Editing of Mutant IDH1 R132H Induces a CpG Methylation-Low State in Patient-Derived Glioma Models of G-CIMP. <i>Molecular Cancer Research</i> , 2019, 17, 2042-2050. | 3.4 | 15 |
| 80 | Inhibition of protein phosphatase PPM1D enhances retinoic acid-induced differentiation in human embryonic carcinoma cell line. <i>Journal of Biochemistry</i> , 2019, 165, 471-477. | 1.7 | 3 |
| 81 | Molecular profiling of tumors of the brainstem by sequencing of CSF-derived circulating tumor DNA. <i>Acta Neuropathologica</i> , 2019, 137, 297-306. | 7.7 | 109 |
| 82 | ABC Transporter Inhibition Plus Dexamethasone Enhances the Efficacy of Convection Enhanced Delivery in H3.3K27M Mutant Diffuse Intrinsic Pontine Glioma. <i>Neurosurgery</i> , 2020, 86, 742-751. | 1.1 | 8 |
| 83 | The Molecular Genetics of Myeloproliferative Neoplasms. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a034876. | 6.2 | 42 |
| 84 | Identification of prognostic markers in diffuse midline gliomas H3K27M mutant. <i>Brain Pathology</i> , 2020, 30, 179-190. | 4.1 | 22 |
| 85 | Radio-Resistance and DNA Repair in Pediatric Diffuse Midline Gliomas. <i>Cancers</i> , 2020, 12, 2813. | 3.7 | 19 |
| 86 | Global activation of oncogenic pathways underlies therapy resistance in diffuse midline glioma. <i>Acta Neuropathologica Communications</i> , 2020, 8, 111. | 5.2 | 19 |
| 87 | Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses. <i>Cancers</i> , 2020, 12, 2194. | 3.7 | 28 |
| 88 | Truncated PPM1D Prevents Apoptosis in the Murine Thymus and Promotes Ionizing Radiation-Induced Lymphoma. <i>Cells</i> , 2020, 9, 2068. | 4.1 | 5 |
| 89 | The integrated genomic and epigenomic landscape of brainstem glioma. <i>Nature Communications</i> , 2020, 11, 3077. | 12.8 | 50 |
| 90 | Metal-dependent Ser/Thr protein phosphatase PPM family: Evolution, structures, diseases and inhibitors. , 2020, 215, 107622. | | 59 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 91 | Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib. <i>Molecular Cancer Research</i> , 2020, 18, 968-980. | 3.4 | 18 |
| 92 | Phosphatase magnesium-dependent 1 \hat{r} (PPM1D), serine/threonine protein phosphatase and novel pharmacological target in cancer. <i>Biochemical Pharmacology</i> , 2021, 184, 114362. | 4.4 | 4 |
| 93 | Malignant Progression of an IDH Mutant Brainstem Glioma in Adult. <i>NMC Case Report Journal</i> , 2021, 8, 301-307. | 0.5 | 3 |
| 94 | Molecular Stratification of Adult and Pediatric High Grade Gliomas. <i>Molecular Pathology Library</i> , 2021, , 123-151. | 0.1 | 0 |
| 95 | From Clonal Hematopoiesis to Therapy-Related Myeloid Neoplasms: The Silent Way of Cancer Progression. <i>Biology</i> , 2021, 10, 128. | 2.8 | 5 |
| 96 | Combined identification of ARID1A, CSMD1, and SENP3 as effective prognostic biomarkers for hepatocellular carcinoma. <i>Aging</i> , 2021, 13, 4696-4712. | 3.1 | 8 |
| 97 | The transcriptional landscape of Shh medulloblastoma. <i>Nature Communications</i> , 2021, 12, 1749. | 12.8 | 47 |
| 99 | A novel assay for screening WIP1 phosphatase substrates in nuclear extracts. <i>FEBS Journal</i> , 2021, 288, 6035-6051. | 4.7 | 1 |
| 100 | Inhibition of the DNA damage response phosphatase PPM1D reprograms neutrophils to enhance anti-tumor immune responses. <i>Nature Communications</i> , 2021, 12, 3622. | 12.8 | 15 |
| 101 | Current knowledge on the immune microenvironment and emerging immunotherapies in diffuse midline glioma. <i>EBioMedicine</i> , 2021, 69, 103453. | 6.1 | 37 |
| 103 | The inhibition of WIP1 phosphatase accelerates the depletion of primordial follicles. <i>Reproductive BioMedicine Online</i> , 2021, 43, 161-171. | 2.4 | 4 |
| 104 | Diffuse midline gliomas, H3 K27M-mutant are associated with less peritumoral edema and contrast enhancement in comparison to glioblastomas, H3 K27M-wildtype of midline structures. <i>PLoS ONE</i> , 2021, 16, e0249647. | 2.5 | 14 |
| 105 | Emerging Advances in Combinatorial Treatments of Epigenetically Altered Pediatric High-Grade H3K27M Gliomas. <i>Frontiers in Genetics</i> , 2021, 12, 742561. | 2.3 | 15 |
| 106 | Polycomb repressive complex 2 in the driver's seat of childhood and young adult brain tumours. <i>Trends in Cell Biology</i> , 2021, 31, 814-828. | 7.9 | 17 |
| 107 | Role of FUT8 expression in clinicopathology and patient survival for various malignant tumor types: a systematic review and meta-analysis. <i>Aging</i> , 2021, 13, 2212-2230. | 3.1 | 5 |
| 108 | Kindlin-2 interacts with \hat{I}^2 -catenin and YB-1 to enhance <i>EGFR</i> transcription during glioma progression. <i>Oncotarget</i> , 2016, 7, 74872-74885. | 1.8 | 27 |
| 109 | Patient-derived DIPG cells preserve stem-like characteristics and generate orthotopic tumors. <i>Oncotarget</i> , 2017, 8, 76644-76655. | 1.8 | 27 |
| 110 | Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity. <i>Oncotarget</i> , 2016, 7, 31623-31638. | 1.8 | 33 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 111 | Diffuse Intrinsic Pontine Glioma: New Pathophysiological Insights and Emerging Therapeutic Targets. <i>Current Neuropharmacology</i> , 2017, 15, 88-97. | 2.9 | 88 |
| 112 | Genomic alterations underlying spinal metastases in pediatric H3K27M-mutant pineal parenchymal tumor of intermediate differentiation: case report. <i>Journal of Neurosurgery: Pediatrics</i> , 2020, 25, 121-130. | 1.3 | 13 |
| 113 | Protein Phosphatase Magnesium-Dependent 1 ⁺ (PPM1D) Expression as a Prognostic Marker in Adult Supratentorial Diffuse Astrocytic and Oligodendroglial Tumors. <i>Journal of Pathology and Translational Medicine</i> , 2018, 52, 71-78. | 1.1 | 2 |
| 114 | Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion. <i>Cancer Research</i> , 2021, 81, 5818-5832. | 0.9 | 10 |
| 115 | Thalamic Gliomas. , 2018, , 1-17. | | 0 |
| 116 | Thalamic Gliomas. , 2020, , 1877-1890. | | 0 |
| 118 | TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist. <i>Acta Neuropathologica Communications</i> , 2021, 9, 178. | 5.2 | 8 |
| 119 | PPM1D Is a Therapeutic Target in Childhood Neural Tumors. <i>Cancers</i> , 2021, 13, 6042. | 3.7 | 5 |
| 120 | Therapeutic Targets in Diffuse Midline Gliomas—An Emerging Landscape. <i>Cancers</i> , 2021, 13, 6251. | 3.7 | 12 |
| 121 | Liquid biopsy detection of genomic alterations in pediatric brain tumors from cell-free DNA in peripheral blood, CSF, and urine. <i>Neuro-Oncology</i> , 2022, 24, 1352-1363. | 1.2 | 29 |
| 122 | PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation. <i>Nature Communications</i> , 2022, 13, 604. | 12.8 | 22 |
| 123 | Innovating Strategies and Tailored Approaches in Neuro-Oncology. <i>Cancers</i> , 2022, 14, 1124. | 3.7 | 3 |
| 124 | Molecular landscape of IDH-wild-type, H3-wild-type glioblastomas of adolescents and young adults. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, . | 3.2 | 0 |
| 125 | Adult diffuse intrinsic pontine glioma: clinical, radiological, pathological, molecular features, and treatments of 96 patients. <i>Journal of Neurosurgery</i> , 2022, 137, 1628-1638. | 1.6 | 4 |
| 126 | Therapeutics Targeting p53-MDM2 Interaction to Induce Cancer Cell Death. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5005. | 4.1 | 38 |
| 127 | AURKA and PLK1 inhibition selectively and synergistically block cell cycle progression in diffuse midline glioma. <i>IScience</i> , 2022, 25, 104398. | 4.1 | 10 |
| 128 | Functionalized Macrophage Exosomes with Panobinostat and PPM1D-siRNA for Diffuse Intrinsic Pontine Gliomas Therapy. <i>Advanced Science</i> , 2022, 9, e2200353. | 11.2 | 29 |
| 129 | Pax3 expression enhances PDGF-B-induced brainstem gliomagenesis and characterizes a subset of brainstem glioma. <i>Acta Neuropathologica Communications</i> , 2014, 2, 134. | 5.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 130 | PPM1D in Solid and Hematologic Malignancies: Friend <i>and</i> Foe?. Molecular Cancer Research, 2022, 20, 1365-1378. | 3.4 | 6 |
| 131 | Tumor-Associated Microenvironment of Adult Gliomas: A Review. Frontiers in Oncology, 0, 12, . | 2.8 | 7 |
| 132 | Development of Antibody-like Proteins Targeting the Oncogenic Ser/Thr Protein Phosphatase PPM1D. Processes, 2022, 10, 1501. | 2.8 | 0 |
| 134 | Uncovering novel mutational signatures by de novo extraction with SigProfilerExtractor. Cell Genomics, 2022, 2, 100179. | 6.5 | 74 |
| 135 | The Effect of Atm Loss on Radiosensitivity of a Primary Mouse Model of Pten-Deleted Brainstem Glioma. Cancers, 2022, 14, 4506. | 3.7 | 3 |
| 136 | Low WIP1 Expression Accelerates Ovarian Aging by Promoting Follicular Atresia and Primordial Follicle Activation. Cells, 2022, 11, 3920. | 4.1 | 1 |
| 137 | PPM1D suppresses p53-dependent transactivation and cell death by inhibiting the Integrated Stress Response. Nature Communications, 2022, 13, . | 12.8 | 9 |
| 138 | Towards Standardisation of a Diffuse Midline Glioma Patient-Derived Xenograft Mouse Model Based on Suspension Matrices for Preclinical Research. Biomedicines, 2023, 11, 527. | 3.2 | 2 |
| 139 | ATM inhibition enhances the efficacy of radiation across distinct molecular subgroups of pediatric high-grade glioma. Neuro-Oncology, 2023, 25, 1828-1841. | 1.2 | 3 |
| 140 | Radiotherapy and radioâ€sensitization in <scp><i>H3</i>^{K27M}</scp>â€mutated diffuse midline gliomas. CNS Neuroscience and Therapeutics, 2023, 29, 1721-1737. | 3.9 | 0 |
| 141 | Histone modification as a drug resistance driver in brain tumors âŽ. , 2016, 2, 216-226. | | 0 |
| 143 | Classification of Brainstem Gliomas Based on Tumor Microenvironment Status. Cancers, 2023, 15, 4224. | 3.7 | 1 |
| 146 | Fimepinostat Impairs NFÂ®B and PI3K/AKT Signaling and Enhances Gemcitabine Efficacy in H3.3K27M-Diffuse Intrinsic Pontine Glioma. Cancer Research, 2024, 84, 598-615. | 0.9 | 0 |
| 147 | Tissue of origin prediction for cancer of unknown primary using a targeted methylation sequencing panel. Clinical Epigenetics, 2024, 16, . | 4.1 | 0 |
| 148 | Therapeutically targeting the unique disease landscape of pediatric high-grade gliomas. Frontiers in Oncology, 0, 14, . | 2.8 | 0 |